CureGene Pharmaceutical key facts
- Developer and provider of drugs designed to treat cardiovascular and cerebrovascular diseases.
- It has raised $27.8M; the latest was Later Stage VC ($13.8M) in May 2025.
- Notable investors include Yonghua Capital, Guangdong Technology Financial Group, Tailong VC, Infinity Group, Hankang Capital — 14 tracked in total.
- Status: Privately Held (backing).
Who backs CureGene Pharmaceutical
14+- ·The complete investor list: 14 names
- ·Watch CureGene Pharmaceutical: the Monday email on marks, rounds and moves
CureGene Pharmaceutical funding rounds
No funding rounds for CureGene Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CureGene Pharmaceutical investors
14 investors are on record for CureGene Pharmaceutical, including Yonghua Capital, Guangdong Technology Financial Group, Tailong VC and Infinity Group.
About CureGene Pharmaceutical
Developer and provider of drugs designed to treat cardiovascular and cerebrovascular diseases. The company focuses on the research and development of innovative drugs in the fields of cardiovascular and cerebrovascular diseases and antiviral diseases. It is currently promoting the clinical development of two dosage forms, intravenous injection and oral tablets, for various indications such as acute coronary syndrome, myocardial infarction, and stroke.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- curegene.com.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
CureGene Pharmaceutical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.